Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome

Critical Care Medicine

Volumn 45, Issue 2, 2017, Pages 253-262

  Mira, Juan C ^a   Gentile, Lori F ^a   Mathias, Brittany J ^a   Efron, Philip A ^a   Brakenridge, Scott C ^a   Mohr, Alicia M ^a   Moore, Frederick A ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

chronic critical illness; immunosuppression; inflammation; myeloid derived suppressor cells; persistent inflammation immunosuppression and catabolism syndrome; shock

Indexed keywords

ARTICLE; CATABOLISM; CELL EXPANSION; CLINICAL OUTCOME; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE COURSE; EFFECTOR CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTE FUNCTION; MYELOID-DERIVED SUPPRESSOR CELL; MYELOPOIESIS; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PERSISTENT INFLAMMATION IMMUNOSUPPRESSION AND CATABOLISM SYNDROME; PRIORITY JOURNAL; SEPSIS; CHRONIC DISEASE; IMMUNOLOGICAL TOLERANCE; INTENSIVE CARE; MEDICAL RESEARCH; METABOLISM; PHYSIOLOGY; PROCEDURES; SYNDROME;

BIOMEDICAL RESEARCH; CHRONIC DISEASE; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; METABOLISM; SEPSIS; SYNDROME;

EID: 84987850874     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002074     Document Type: Article

References (106)

1. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316: 552-554
2. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89: 1551-1557
3. Alexander HR, Doherty GM, Buresh CM, et al A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991; 173: 1029-1032
4. Giroir BP. Mediators of septic shock: New approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 1993; 21: 780-789
5. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655
6. Marshall JC. Why have clinical trials in sepsis failed?. Trends Mol Med 2014; 20: 195-203
7. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-555
8. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 201; 41: 580-637
9. Rhodes A, Phillips G, Beale R, et al. The Surviving Sepsis Campaign bundles and outcome: Results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study). Intensive Care Med 2015; 41: 1620-1628
10. Gao F, Melody T, Daniels DF, et al. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: A prospective observational study. Crit Care 2005; 9: R764-R770
11. Castellanos-Ortega A, Suberviola B, García-Astudillo LA, et al. Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year followup quasi-experimental study. Crit Care Med 2010; 38: 1036-1043
12. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36: 222-231
13. Levy MM, Rhodes A, Phillips GS, et al. Surviving Sepsis Campaign: Association between performance metrics and outcomes in a 7.5-year study. Crit Care Med 2015; 43: 3-12
14. Stoller J, Halpin L, Weis M, et al. Epidemiology of severe sepsis: 2008-2012. J Crit Care 2015; 31: 58-62
15. Iwashyna TJ, Cooke CR, Wunsch H, et al. Population burden of longterm survivorship after severe sepsis in older Americans. J Am Geriatr Soc 2012; 60: 1070-1077
16. Hall MJ, Williams SN, DeFrances CJ, et al. Inpatient care for septicemia or sepsis: A challenge for patients and hospitals. NCHS Data Brief 2011; 1-8
17. Dellinger RP. Foreword. The future of sepsis performance improvement. Crit Care Med 2015; 43: 1787-1789
18. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801-810
19. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 762-774
20. Karlsson S, Ruokonen E, Varpula T, et al. Finnsepsis Study Group: Long-Term outcome and quality-Adjusted life years after severe sepsis. Crit Care Med 2009; 37: 1268-1274
21. Borges RC, Carvalho CR, Colombo AS, et al. Physical activity, muscle strength, and exercise capacity 3 months after severe sepsis and septic shock. Intensive Care Med 2015; 41: 1433-1444
22. Widmann CN, Heneka MT. Long-Term cerebral consequences of sepsis. Lancet Neurol 2014; 13: 630-636
23. Iwashyna TJ, Ely EW, Smith DM, et al. Long-Term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010; 304: 1787-1794
24. Yende S, Linde-Zwirble W, Mayr F, et al. Risk of cardiovascular events in survivors of severe sepsis. Am J Respir Crit Care Med 2014; 189: 1065-1074
25. Walkey AJ, Hammill BG, Curtis LH, et al. Long-Term outcomes following development of new-onset atrial fibrillation during sepsis. Chest 2014; 146: 1187-1195
26. Heyland DK, Hopman W, Coo H, et al. Long-Term health-related quality of life in survivors of sepsis. Short Form 36: A valid and reliable measure of health-related quality of life. Crit Care Med 2000; 28: 3599-3605
27. Battle CE, Davies G, Evans PA. Long term health-related quality of life in survivors of sepsis in South West Wales: An epidemiological study. PLoS One 2014; 9: e116304
28. Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 2012; 72: 1491-1501
29. Robertson CM, Coopersmith CM. The systemic inflammatory response syndrome. Microbes Infect 2006; 8: 1382-1389
30. Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 2008; 29: 617-625, viii
31. Rosenthal MD, Moore FA. Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. J Adv Nutr Hum Metab 2015; 1: e784
32. Marini JJ, Vincent JL, Annane D. Critical care evidence-new directions. JAMA 2015; 313: 893-894
33. Lamas D. Chronic critical illness. N Engl J Med 2014; 370: 175-177
34. Kahn JM, Le T, Angus DC, et al. ProVent Study Group Investigators: The epidemiology of chronic critical illness in the United States. Crit Care Med 2015; 43: 282-287
35. Cox CE. Persistent systemic inflammation in chronic critical illness. Respir Care 2012; 57: 859-864
36. Kandilov A, Ingber M, Morley M, et al. Chronically Critically Ill Population Payment Recommendations (CCIP-PR). Durham, NC, Reasearch Triangle Institute, 2014, pp 21-65
37. Carson SS, Bach PB. The epidemiology and costs of chronic critical illness. Crit Care Clin 2002; 18: 461-476
38. Marchioni A, Fantini R, Antenora F, et al. Chronic critical illness: The price of survival. Eur J Clin Invest 2015; 45: 1341-1349
39. Cox CE, Carson SS, Lindquist JH, et al. Quality of Life After Mechanical Ventilation in the Aged (QOL-MV) Investigators: Differences in oneyear health outcomes and resource utilization by definition of prolonged mechanical ventilation: A prospective cohort study. Crit Care 2007; 11: R9
40. Scheinhorn DJ, Hassenpflug MS, Votto JJ, et al. Ventilation Outcomes Study Group: Post-ICU mechanical ventilation at 23 long-Term care hospitals: A multicenter outcomes study. Chest 2007; 131: 85-93
41. Iwashyna TJ, Hodgson CL, Pilcher D, et al. Timing of onset and burden of persistent critical illness in Australia and New Zealand: A retrospective, population-based, observational study. Lancet Respir Med 2016; 4: 566-573
42. Needham DM, Davidson J, Cohen H, et al. Improving long-Term outcomes after discharge from intensive care unit: Report from a stakeholders? conference. Crit Care Med 2012; 40: 502-509
43. Deutschman CS, Raj NR, McGuire EO, et al. Orexinergic activity modulates altered vital signs and pituitary hormone secretion in experimental sepsis. Crit Care Med 2013; 41: e368-e375
44. Silverman HA, Dancho M, Regnier-Golanov A, et al. Brain regionspecific alterations in the gene expression of cytokines, immune cell markers and cholinergic system components during peripheral endotoxin-induced inflammation. Mol Med 2014; 20: 601-611
45. Furze RC, Rankin SM. Neutrophil mobilization and clearance in the bone marrow. Immunology 2008; 125: 281-288
46. Scumpia PO, Kelly-Scumpia KM, Delano MJ, et al. Cutting edge: Bacterial infection induces hematopoietic stem and progenitor cell expansion in the absence of TLR signaling. J Immunol 2010; 184: 2247-2251
47. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med 2005; 201: 1771-1780
48. Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol 2014; 14: 302-314
49. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174
50. Dilek N, Vuillefroy de Silly R, Blancho G, et al. Myeloid-derived suppressor cells: Mechanisms of action and recent advances in their role in transplant tolerance. Front Immunol 2012; 3: 208
51. Bronte V. Myeloid-derived suppressor cells in inflammation: Uncovering cell subsets with enhanced immunosuppressive functions. Eur J Immunol 2009; 39: 2670-2672
52. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13: 739-752
53. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204: 1463-1474
54. Makarenkova VP, Bansal V, Matta BM, et al. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 2006; 176: 2085-2094
55. Derive M, Bouazza Y, Alauzet C, et al. Myeloid-derived suppressor cells control microbial sepsis. Intensive Care Med 2012; 38: 1040-1049
56. Popovic PJ, Zeh HJ 3rd, Ochoa JB. Arginine and immunity. J Nutr 2007; 137: 1681S-1686S
57. Bronte V, Zanovello P. Regulation of immune responses by L-Arginine metabolism. Nat Rev Immunol 2005; 5: 641-654
58. Heim CE, Vidlak D, Kielian T. Interleukin-10 production by myeloidderived suppressor cells contributes to bacterial persistence during Staphylococcus aureus orthopedic biofilm infection. J Leukoc Biol 2015; 98: 1003-1013
59. Lei GS, Zhang C, Lee CH. Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia. Infect Immun 2015; 83: 572-582
60. Huang H, Zhang G, Li G, et al. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. Tumour Biol 2015; 36: 7987-7996
61. Cuenca AG, Delano MJ, Kelly-Scumpia KM, et al A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 2011; 17: 281-292
62. Noel JG, Osterburg A, Wang Q, et al. Thermal injury elevates the inflammatory monocyte subpopulation in multiple compartments. Shock 2007; 28: 684-693
63. Janols H, Bergenfelz C, Allaoui R, et al A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in grampositive cases. J Leukoc Biol 2014; 96: 685-693
64. Mathias B, Delmas AL, Ozrazgat-Baslanti T, et al. Human myeloidderived suppressor cells are associated with chronic immune suppression after severe sepsis/septic shock. Ann Surg 2016 May 9. [Epub ahead of print]
65. Moisey LL, Mourtzakis M, Cotton BA, et al. Nutrition and Rehabilitation Investigators Consortium (NUTRIC): Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. Crit Care 2013; 17: R206
66. Le Maguet P, Roquilly A, Lasocki S, et al. Prevalence and impact of frailty on mortality in elderly ICU patients: A prospective, multicenter, observational study. Intensive Care Med 2014; 40: 674-682
67. Bagshaw SM, Stelfox HT, McDermid RC, et al. Association between frailty and short- And long-Term outcomes among critically ill patients: A multicentre prospective cohort study. CMAJ 2014; 186: E95-E102
68. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300: 413-422
69. Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med 2009; 37: 2350-2358
70. Libert N, Bigaillon C, Chargari C, et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients. Biomed J 2015; 38: 70-76
71. Huang A, Zhang B, Wang B, et al. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother 2013; 62: 1439-1451
72. Chen MF, Kuan FC, Yen TC, et al. IL-6-stimulated CD11b+ CD14+HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget 2014; 5: 8716-8728
73. Blum D, Stene GB, Solheim TS, et al. Euro-Impact: Validation of the consensus-definition for cancer cachexia and evaluation of a classification model-A study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol 2014; 25: 1635-1642
74. Chen J, Chen Z. The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol 2014; 31: 82
75. Meirow Y, Kanterman J, Baniyash M. Paving the road to tumor development and spreading: Myeloid-derived suppressor cells are ruling the fate. Front Immunol 2015; 6: 523
76. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumorbearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-6721
77. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70: 3052-3061
78. Yuan H, Cai P, Li Q, et al. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. Biomed Pharmacother 2014; 68: 751-756
79. Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med 2014; 6: 237ra267
80. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloidderived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157
81. Mirza N, Fishman M, Fricke I, et al. All-Trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-9307
82. Cuenca AG, Cuenca AL, Winfield RD, et al. Novel role for tumorinduced expansion of myeloid-derived cells in cancer cachexia. J Immunol 2014; 192: 6111-6119
83. Kang JW, Kim SJ, Cho HI, et al. DAMPs activating innate immune responses in sepsis. Ageing Res Rev 2015; 24: 54-65
84. Timmermans K, Kox M, Scheffer GJ, et al. Danger in the intensive care unit: Damps in critically ill patients. Shock 2016; 45: 108-116
85. Yamanouchi S, Kudo D, Yamada M, et al. Plasma mitochondrial DNA levels in patients with trauma and severe sepsis: Time course and the association with clinical status. J Crit Care 2013; 28: 1027-1031
86. Gao S, Yang Y, Fu Y, et al. Diagnostic and prognostic value of myeloid-related protein complex 8/14 for sepsis. Am J Emerg Med 2015; 33: 1278-1282
87. White LE, Hassoun HT, Bihorac A, et al. Acute kidney injury is surprisingly common and a powerful predictor of mortality in surgical sepsis. J Trauma Acute Care Surg 2013; 75: 432-438
88. Korenkevych D, Ozrazgat-Baslanti T, Thottakkara P, et al. The pattern of longitudinal change in serum creatinine and 90-day mortality after major surgery. Ann Surg 2015; 263: 1219-1227
89. Villar J, Blanco J, Zhang H, et al. Ventilator-induced lung injury and sepsis: Two sides of the same coin?. Minerva Anestesiol 2011; 77: 647-653
90. Schepens T, Verbrugghe W, Dams K, et al. The course of diaphragm atrophy in ventilated patients assessed with ultrasound: A longitudinal cohort study. Crit Care 2015; 19: 422
91. Powers SK, Wiggs MP, Sollanek KJ, et al. Ventilator-induced diaphragm dysfunction: Cause and effect. Am J Physiol Regul Integr Comp Physiol 2013; 305: R464-R477
92. Hotchkiss RS, Opal S. Immunotherapy for sepsis-A new approach against an ancient foe. N Engl J Med 2010; 363: 87-89
93. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med 2014; 371: 380-383
94. Oberholzer C, Oberholzer A, Clare-Salzler M, et al. Apoptosis in sepsis: A new target for therapeutic exploration. FASEB J 2001; 15: 879-892
95. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A 1999; 96: 14541-14546
96. Hotchkiss RS, Chang KC, Swanson PE, et al. Caspase inhibitors improve survival in sepsis: A critical role of the lymphocyte. Nat Immunol 2000; 1: 496-501
97. Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 2010; 184: 3768-3779
98. Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2010; 184: 1401-1409
99. Chang KC, Burnham CA, Compton SM, et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013; 17: R85
100. Shindo Y, Unsinger J, Burnham CA, et al. Interleukin-7 and antiprogrammed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. Shock 2015; 43: 334-343
101. Lee JM, Kim EK, Seo H, et al. Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloid-derived suppressor cells via TLR2-dependent STAT3 activation. Eur J Immunol 2014; 44: 1672-1684
102. Chun E, Lavoie S, Michaud M, et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep 2015; 12: 244-257
103. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13: 828-835
104. Chioda M, Marigo I, Mandruzzato S, et al. Arginase, nitric oxide synthase, and novel inhibitors of L-Arginine metabolism in immune modulation. In. Cancer Immunotherapy. Second Edition. Prendergast GC, Jaffee EM (Eds). San Diego, Academic Press, 2013, pp 597-634
105. Zhu J, Huang X, Yang Y. Myeloid-derived suppressor cells regulate natural killer cell response to adenovirus-mediated gene transfer. J Virol 2012; 86: 13689-13696
106. Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70: 99-108